Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 12/2005

01-12-2005 | Review

Regulatory T cells and tumor immunity

Authors: Subhasis Chattopadhyay, Nitya G. Chakraborty, Bijay Mukherji

Published in: Cancer Immunology, Immunotherapy | Issue 12/2005

Login to get access

Abstract

Central deletion of “self-reactive” T cells has been the textbook paradigm for inducing “self-tolerance” in the periphery and the concept of a role of T cell-mediated suppression in this process has long been controversial. A decisive shift in the opinion on suppressor T cells has lately occurred with the observations of Sakaguchi’s group that linked a class of CD4+CD25+ T cells to the prevention of autoimmunity from neonatal thymectomy in mice. These CD4+CD25+ T cells have been named T regulatory (Treg) cells. They are believed to be selected in the thymus as an anti-self repertoire. Hence they were referred to as natural T regulatory (nTreg) cells. Presently, in addition to their role in autoimmunity, they are believed to exert regulatory function in infection, in transplantation immunity as well as in tumor immunity. In contrast to these nTreg cells, another class of CD4+ Treg cells also exercises regulatory function in the periphery. These Treg cells are also CD4+ T cells and after activation they also become phenotypically CD4+CD25+. They are, however induced in the periphery as Treg cells. Hence, they are termed as induced Treg (iTreg) cells. There are major differences in the biology of these two types of Treg cells. They differ in their requirements for activation and in their mode of action. Nonetheless, evidence indicates that both nTreg cells and iTreg cells are involved in the control of tumor immunity. The question of how to circumvent their regulatory constraints, therefore, has become a major challenge for tumor immunologists.
Literature
1.
go back to reference Gershon RK, Kondo K (1970) Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18:723PubMed Gershon RK, Kondo K (1970) Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18:723PubMed
2.
go back to reference Moller G (1988) Do suppressor T cells exist? Scand J Immunol 27:247PubMed Moller G (1988) Do suppressor T cells exist? Scand J Immunol 27:247PubMed
3.
go back to reference Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531CrossRefPubMed Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531CrossRefPubMed
4.
5.
go back to reference Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: I. Requirement of Lyt-1 effector cells for oocyte damage after adoptive transfer. J Exp Med 156:156 Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: I. Requirement of Lyt-1 effector cells for oocyte damage after adoptive transfer. J Exp Med 156:156
6.
go back to reference Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: II. Requirement of Lyt-1 effector cells in normal female mice for the prevention of oophoritis. J Exp Med 156:1577CrossRefPubMed Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: II. Requirement of Lyt-1 effector cells in normal female mice for the prevention of oophoritis. J Exp Med 156:1577CrossRefPubMed
7.
go back to reference Sakaguchi S, Fukuma K, Kuribiashi K, Masuda T (1985) Organ specific autoimmunie diseases induced in mice by elimination of T cell subsets. I. Evidence for the active participation of T cells in natural self-tolerance: deficit of a subset as possible cause of autoimmunity. J Exp Med 161:72CrossRefPubMed Sakaguchi S, Fukuma K, Kuribiashi K, Masuda T (1985) Organ specific autoimmunie diseases induced in mice by elimination of T cell subsets. I. Evidence for the active participation of T cells in natural self-tolerance: deficit of a subset as possible cause of autoimmunity. J Exp Med 161:72CrossRefPubMed
8.
go back to reference Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self tolerance maintained by activated T cells expressing IL-2 receptor a-chain (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151PubMed Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self tolerance maintained by activated T cells expressing IL-2 receptor a-chain (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151PubMed
9.
go back to reference Berendt MJ, North RJ (1980) T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69CrossRefPubMed Berendt MJ, North RJ (1980) T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69CrossRefPubMed
10.
go back to reference North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1PubMed North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1PubMed
11.
go back to reference Mukherji B, Wilhelm SA, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136:1888PubMed Mukherji B, Wilhelm SA, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136:1888PubMed
12.
go back to reference Mukherji B, Nashed AL, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol 136:1893PubMed Mukherji B, Nashed AL, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol 136:1893PubMed
13.
go back to reference Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961CrossRefPubMed Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961CrossRefPubMed
14.
go back to reference Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 26:455CrossRef Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 26:455CrossRef
15.
go back to reference Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki Y, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahasi T (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18CrossRefPubMed Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki Y, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahasi T (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18CrossRefPubMed
16.
go back to reference Piccirillo CA, Shevach EM (2004) Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 16:81CrossRefPubMed Piccirillo CA, Shevach EM (2004) Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 16:81CrossRefPubMed
17.
go back to reference O’Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nature Med 10:801CrossRefPubMed O’Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nature Med 10:801CrossRefPubMed
19.
20.
go back to reference Ehrlich P (1909) Nederlandsch Tijdschrift voor Geneeskunde: Ueber den jetzigne Stand Der Karzinomforchung. Weekblad Jaargang Eerst helft 5:273 Ehrlich P (1909) Nederlandsch Tijdschrift voor Geneeskunde: Ueber den jetzigne Stand Der Karzinomforchung. Weekblad Jaargang Eerst helft 5:273
21.
go back to reference Srivastava PK, Old LJ (1988) Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9:78CrossRefPubMed Srivastava PK, Old LJ (1988) Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9:78CrossRefPubMed
22.
go back to reference Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725CrossRefPubMed Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725CrossRefPubMed
23.
go back to reference Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175CrossRefPubMed Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175CrossRefPubMed
24.
go back to reference Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 54:187CrossRefPubMed Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 54:187CrossRefPubMed
26.
27.
go back to reference Marincola FM, Jaffee EM, Hiclin DJ, Ferrone S (2000) Escape of human solid tumors from T cell-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181PubMed Marincola FM, Jaffee EM, Hiclin DJ, Ferrone S (2000) Escape of human solid tumors from T cell-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181PubMed
28.
go back to reference Pawlec (2004) Tumor escape from the immune response. Cancer Immunol Immunother 53:843PubMed Pawlec (2004) Tumor escape from the immune response. Cancer Immunol Immunother 53:843PubMed
29.
go back to reference Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy; possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844CrossRefPubMed Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy; possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844CrossRefPubMed
30.
go back to reference Anichini A, Vigetti C, Mortini R (2004) The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53:855CrossRefPubMed Anichini A, Vigetti C, Mortini R (2004) The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53:855CrossRefPubMed
31.
go back to reference Whiteside TL (2004) Down-regulation of the z-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865PubMed Whiteside TL (2004) Down-regulation of the z-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865PubMed
32.
go back to reference Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1999) Emergence of Th2 type CD4+ T cell response to repetitive stimulation with antigen and antigen presenting cells, in vitro: Implications in designing tumor vaccines. J Immunol 162:5576PubMed Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1999) Emergence of Th2 type CD4+ T cell response to repetitive stimulation with antigen and antigen presenting cells, in vitro: Implications in designing tumor vaccines. J Immunol 162:5576PubMed
33.
go back to reference Mukherji B, Guha A, Loomis R, Ergin MT (1987) Cell-mediated amplification and down-regulation of cytotoxic immune response against autologous human cancer. J Immunol 138:1987PubMed Mukherji B, Guha A, Loomis R, Ergin MT (1987) Cell-mediated amplification and down-regulation of cytotoxic immune response against autologous human cancer. J Immunol 138:1987PubMed
34.
go back to reference Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B (1990) Autologous melanoma-induced activation of regulatory T cells that suppress cytolytic response. J Immunol 145:2359PubMed Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B (1990) Autologous melanoma-induced activation of regulatory T cells that suppress cytolytic response. J Immunol 145:2359PubMed
35.
go back to reference Mukherji B, Chakraborty NG, Sivanandham M (1990) T cell clones that react against human tumors. Immunol Rev 116:33PubMed Mukherji B, Chakraborty NG, Sivanandham M (1990) T cell clones that react against human tumors. Immunol Rev 116:33PubMed
36.
go back to reference Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T cell subset inhibits antigen specific T cell responses and prevents colitis. Nature 389:737CrossRefPubMed Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T cell subset inhibits antigen specific T cell responses and prevents colitis. Nature 389:737CrossRefPubMed
37.
go back to reference Roncarolo MG, Bachetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68CrossRefPubMed Roncarolo MG, Bachetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68CrossRefPubMed
38.
go back to reference Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B (2004) Regulatory T cells response and tumor vaccine induced CTL in human melanoma. Human Immunol 65:794CrossRefPubMed Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B (2004) Regulatory T cells response and tumor vaccine induced CTL in human melanoma. Human Immunol 65:794CrossRefPubMed
39.
go back to reference Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF (2004) Tumor specific human CD4+ regulatory T cells and their ligands: implications for immunottherapy. Immunity 20:107CrossRefPubMed Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF (2004) Tumor specific human CD4+ regulatory T cells and their ligands: implications for immunottherapy. Immunity 20:107CrossRefPubMed
40.
go back to reference Shimizu J. Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211PubMed Shimizu J. Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211PubMed
41.
go back to reference Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukine-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128PubMed Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukine-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128PubMed
42.
43.
go back to reference Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocytes-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocytes responses. J Exp Med 194:823CrossRefPubMed Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocytes-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocytes responses. J Exp Med 194:823CrossRefPubMed
44.
go back to reference Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A (2002) Depletion of CD25+ regulatory cells in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunol 2:1 Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A (2002) Depletion of CD25+ regulatory cells in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunol 2:1
45.
go back to reference Wei-Zen W, Morris GP, Kong Yi-chi M (2004) Antitumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73CrossRefPubMed Wei-Zen W, Morris GP, Kong Yi-chi M (2004) Antitumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73CrossRefPubMed
46.
go back to reference Tanaka H, Tanaka J, Jorgen K, Shu S (2002) Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207CrossRef Tanaka H, Tanaka J, Jorgen K, Shu S (2002) Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207CrossRef
47.
go back to reference Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine rejection antigens. Eur J Immunol 32:3267CrossRefPubMed Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine rejection antigens. Eur J Immunol 32:3267CrossRefPubMed
48.
go back to reference Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients inhibit autologous T cell proliferation. J Immunol 168:4272PubMed Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients inhibit autologous T cell proliferation. J Immunol 168:4272PubMed
49.
go back to reference Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+D25+ regulatory T cells suppress tumor immunity sensitive to cyclophosphamide which allows immunotherapy in established tumors to be curative. Eur J Immunol 34:336CrossRefPubMed Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+D25+ regulatory T cells suppress tumor immunity sensitive to cyclophosphamide which allows immunotherapy in established tumors to be curative. Eur J Immunol 34:336CrossRefPubMed
50.
go back to reference Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171:5931PubMed Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171:5931PubMed
51.
go back to reference Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 20:771CrossRef Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 20:771CrossRef
52.
go back to reference Liyanage UK, Moore TT, Joo HG, Tanaka Y, Hermann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756PubMed Liyanage UK, Moore TT, Joo HG, Tanaka Y, Hermann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756PubMed
53.
go back to reference Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267PubMed Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267PubMed
54.
go back to reference Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606PubMed Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606PubMed
55.
go back to reference Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2003) Immunosuppressive regulatory T cells ate abundant in tumor lymphocytes of Hodgkins lymphoma. Blood 103:1755CrossRefPubMed Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2003) Immunosuppressive regulatory T cells ate abundant in tumor lymphocytes of Hodgkins lymphoma. Blood 103:1755CrossRefPubMed
56.
go back to reference Javia LR, Rosenberg SA (2003) CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26:85CrossRefPubMed Javia LR, Rosenberg SA (2003) CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26:85CrossRefPubMed
57.
58.
go back to reference Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942CrossRefPubMed Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942CrossRefPubMed
59.
go back to reference Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+CD25+ regulatory T cells are overexpressed in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444PubMed Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+CD25+ regulatory T cells are overexpressed in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444PubMed
60.
go back to reference Cozzo C, Larkin J III, Caton AJ (2003) Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 171:5678PubMed Cozzo C, Larkin J III, Caton AJ (2003) Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 171:5678PubMed
61.
go back to reference Thronton AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287CrossRefPubMed Thronton AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287CrossRefPubMed
62.
go back to reference Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S (1999) Thymus and autoimmunity: Production of CD25+CD4+ Naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317PubMed Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S (1999) Thymus and autoimmunity: Production of CD25+CD4+ Naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317PubMed
63.
go back to reference Baecher-Allan C, Viglietta V, Hafler DA (2002) Inhibition of human CD(+)CD25(+high) regulatory T cell function. J Immunol 169:6210PubMed Baecher-Allan C, Viglietta V, Hafler DA (2002) Inhibition of human CD(+)CD25(+high) regulatory T cell function. J Immunol 169:6210PubMed
64.
go back to reference Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger R (2004) Large-scale in vitro expansion of polyclonal human CD4(+) CD25high regulatory T cells. Blood 104:895CrossRefPubMed Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger R (2004) Large-scale in vitro expansion of polyclonal human CD4(+) CD25high regulatory T cells. Blood 104:895CrossRefPubMed
65.
go back to reference Thronton AM, Picirillo CA, Shevach EM (2004) Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 24:366CrossRef Thronton AM, Picirillo CA, Shevach EM (2004) Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 24:366CrossRef
66.
go back to reference Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172:6519PubMed Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172:6519PubMed
67.
go back to reference Malek TR (2003) The main function of IL-2 is to promote the development of regulatory T cells. J Leukoc Biol 74:961CrossRefPubMed Malek TR (2003) The main function of IL-2 is to promote the development of regulatory T cells. J Leukoc Biol 74:961CrossRefPubMed
68.
go back to reference Suri-Payer E, Cantor H (2001) Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+CD25+ T cells. J Autoimmun 16:115CrossRefPubMed Suri-Payer E, Cantor H (2001) Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+CD25+ T cells. J Autoimmun 16:115CrossRefPubMed
69.
go back to reference Asseman C, Mauze S, Leach M, Coffman Rl, Powrie F (1999) An essential role for interleukin-10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190:995CrossRefPubMed Asseman C, Mauze S, Leach M, Coffman Rl, Powrie F (1999) An essential role for interleukin-10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190:995CrossRefPubMed
70.
go back to reference Balkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sachs DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502CrossRefPubMed Balkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sachs DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502CrossRefPubMed
71.
go back to reference Takahashi T, Tagami T, Yamazuki S, Ueda T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Dominant immunologic self-tolerance by CD4+CD25+ regulatory T cells constitutively expressing CTLA-4. J Exp Med 192:303CrossRefPubMed Takahashi T, Tagami T, Yamazuki S, Ueda T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Dominant immunologic self-tolerance by CD4+CD25+ regulatory T cells constitutively expressing CTLA-4. J Exp Med 192:303CrossRefPubMed
72.
go back to reference Read S, Maimstrom S, Powrie F (2000) CTLA-4 plays an essential role in the function of CD4+CD25+ regulatory cells which control intestinal inflammation. J Exp Med 192:295CrossRefPubMed Read S, Maimstrom S, Powrie F (2000) CTLA-4 plays an essential role in the function of CD4+CD25+ regulatory cells which control intestinal inflammation. J Exp Med 192:295CrossRefPubMed
73.
go back to reference Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface bound transformation growth factor beta. J Exp Med 194:629CrossRefPubMed Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface bound transformation growth factor beta. J Exp Med 194:629CrossRefPubMed
74.
go back to reference Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S (2002) Phenotype localization and mechanism of suppression of CD4+CD25+ human thymocytes. J Exp Med 196:379CrossRefPubMed Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S (2002) Phenotype localization and mechanism of suppression of CD4+CD25+ human thymocytes. J Exp Med 196:379CrossRefPubMed
75.
go back to reference Levings MK, Bacchetta R, Schulz U, Roncarolo MG (2002) The role of IL-10 and TGF beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 129:263CrossRefPubMed Levings MK, Bacchetta R, Schulz U, Roncarolo MG (2002) The role of IL-10 and TGF beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 129:263CrossRefPubMed
76.
go back to reference Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137PubMed Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137PubMed
77.
go back to reference Cederbom L, Hall H, Ivars F (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30:1538CrossRefPubMed Cederbom L, Hall H, Ivars F (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30:1538CrossRefPubMed
78.
go back to reference Misra N, Bayry J, Lacroix-demazes S, Kazatcchkine MD, Kaveri SV (2004) Cutting Edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676PubMed Misra N, Bayry J, Lacroix-demazes S, Kazatcchkine MD, Kaveri SV (2004) Cutting Edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676PubMed
79.
go back to reference Gett AV, Sallusto F, Lanzavecchia A, Geginat J (2003) T cell fitness determined by signal strength. Nat Immunol 4:355CrossRefPubMed Gett AV, Sallusto F, Lanzavecchia A, Geginat J (2003) T cell fitness determined by signal strength. Nat Immunol 4:355CrossRefPubMed
80.
go back to reference Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B (2004) Rescuing melanoma epitope specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunoterapy. J Immunol 173:6017PubMed Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B (2004) Rescuing melanoma epitope specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunoterapy. J Immunol 173:6017PubMed
81.
go back to reference North RJ (1982) Cyclophosphamode-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063CrossRefPubMed North RJ (1982) Cyclophosphamode-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063CrossRefPubMed
82.
go back to reference North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90PubMed North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90PubMed
83.
go back to reference Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T -cells. Cancer Res 48:1671PubMed Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T -cells. Cancer Res 48:1671PubMed
84.
go back to reference Michiels J-P H, Reilly RT, Emens LA, Ercollini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immmune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689PubMed Michiels J-P H, Reilly RT, Emens LA, Ercollini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immmune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689PubMed
85.
go back to reference Shevach EM (2002) CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389PubMed Shevach EM (2002) CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389PubMed
86.
go back to reference Cohn M (2004) Whither T-suppressors: if they did not exist would we have to invent them? Cell Immunol 227:81CrossRefPubMed Cohn M (2004) Whither T-suppressors: if they did not exist would we have to invent them? Cell Immunol 227:81CrossRefPubMed
Metadata
Title
Regulatory T cells and tumor immunity
Authors
Subhasis Chattopadhyay
Nitya G. Chakraborty
Bijay Mukherji
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2005
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-005-0699-9

Other articles of this Issue 12/2005

Cancer Immunology, Immunotherapy 12/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine